Cullinan Therapeutics (CGEM) Revenue (2021)

Cullinan Therapeutics' (CGEM) quarterly Revenue came in at $18.9 million in Q1 2021.

Cullinan Therapeutics (CGEM) Revenue (2021) Analysis & Trends

Cullinan Therapeutics' Revenue history runs 1 years deep, the most recent figure standing at $18.9 million for Q1 2021.

  • On a quarterly basis, Revenue changed N/A year-over-year to $18.9 million in Q1 2021; TTM through Dec 2021 was $18.9 million, a N/A change from a year earlier, with the FY2021 full-year figure at $18.9 million, changed N/A from the prior year.
  • Revenue held at $18.9 million in Q1 2021 per CGEM's latest filing.
  • Across five years, Revenue topped out at $18.9 million in Q1 2021 and bottomed at $18.9 million in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.51 Bn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 1.56 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Cullinan Therapeutics 368.65 Mn 368.65 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2021 18.94 Mn